Fresh concerns have emerged over the safety of Moderna’s experimental respiratory syncytial virus (RSV) vaccines for infants following the disclosure of 13 suspected serious adverse drug reactions recorded during a clinical trial in the United Kingdom. The latest information, obtained from the UK Medicines and Healthcare products Regulatory Agency (MHRA), has raised questions about the safety monitoring and reporting of the trial, which was susp…
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.